SEATTLE, WA -- (MARKET WIRE) -- October 25, 2006 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector technology that describes delivery of genes or delivery of small therapeutic genetic constructs or small therapeutic genetic constructs including therapeutic RNA molecules such as RNAi. U.S. patent #7,125,717 entitled “Metabolically Activated Recombinant Viral Vectors and Methods for Their Preparation and Use” describes the use of AAV vectors that are more efficient for expression of therapeutic genetic constructs.
